SEC Filings

8-K
PERNIX THERAPEUTICS HOLDINGS, INC. filed this Form 8-K on 02/19/2019
Entire Document
 

 

46 2017 A - 2022 E Net Product Sales • Recent declines in performance impacted by ( i ) withdrawal of IDA (1) in Q4 2017 (2017A net sales of $14.9M) and (ii) withdrawal of desvenlafaxine in Q1 2018 (2017A net sales of $3.3M) • Remaining portfolio provides a steady cash flow stream • Assumes a 5% decline in sales in the out years ($ in millions) Note: Projections are subject to numerous assumptions and risks. ( 1 ) Isometheptene /Dichloralphenazone/APAP Capsules. $13 $9 $9 $9 $8 $8 $15 $3 53% 45% 45% 38% 38% 38% 0% 10% 20% 30% 40% 50% 60% $0 $5 $10 $15 $20 $25 $30 $35 2017A 2018E 2019E 2020E 2021E 2022E Continued Generics Sales Discontinued - IDA Discontinued - Desvenlafaxine Gross Margin Generic and Other Branded Net Sales A A